For a better experience, click the Compatibility Mode icon above to turn off Compatibility Mode, which is only for viewing older websites.

Rain Therapeutics signs license agreement with Drexel

August 25, 2020

Rain Therapeutics Inc., a privately-held, clinical stage biotechnology company focused on targeted therapies for patients with cancer, today announces the signing of an exclusive, worldwide license agreement of a Drexel University research program to Rain for small molecule inhibitors of RAD52, a critical molecule involved in the DNA damage response (DDR) pathway. The agreement expands Rain’s targeted oncology pipeline to include synthetic lethal strategies for the treatment of cancers associated with mutations in the DDR pathway, including breast and ovarian cancers characterized by BRCA1/2 mutations.